Articles

Why the history of life sciences still matters

Explore the history of life sciences and the pioneering discoveries, people, and innovation hubs that shaped modern medicine and continue to drive scientific progress.

How to turn patient insights into cross-functional decisions

Learn how pharma teams can turn patient and advocate feedback into decisions across launch, access, evidence, and commercial planning with a six-step model.

Acumetis expands global Medical Affairs team with new scientific and strategic talent

Acumetis welcomes Kate Ashworth, Angie Gao, and Liz Reader to its growing Medical Affairs team, expanding global medical affairs expertise.

From listening to action: How patient voice becomes patient insight

Download of white paper to explore how to turn patient voice into decision-ready insights that improve trial communications, launches, support, market access, and trust.

Meet Acumetis at ISPOR Europe 2026!

Meet Acumetis at ISPOR EU 2026 in Vienna. From PICO development and Joint Clinical Assessments to HEOR and market access, discover how Acumetis helps organizations turn evidence into value.

Siloed by design: the integration problem in market access

Explore how increasingly interconnected evidence, pricing, HTA, and launch decisions are reshaping the role of Market Access, and the capabilities teams need to influence decisions earlier.

Acumetis appoints Ramil Burden as Chief Executive Officer

Acumetis has announced the appointment of Ramil Burden as Chief Executive Officer, effective September 14, 2026.

From funding to future access: Why early value planning matters in drug development

Learn how early value planning in drug development can strengthen biotech investment cases, guide evidence generation, reduce market access risk, and support future reimbursement.

Meet Acumetis at PHLEX 2026!

Attending PHLEX 2026? Meet with Acumetis to discuss your launch priorities and how we can help turn strategy into confident execution.